Investigational drug · Phase 3
PCV21 vaccine
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pneumococcal Immunization, Healthy Volunteers.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
13
Any phase or sponsor naming "PCV21 vaccine"
First trial start
2024
Dec 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PCV21 vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Immunization
- Healthy Volunteers
Largest trials
Live from ClinicalTrials.gov: studies naming "PCV21 vaccine" as an intervention, largest first.
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Pivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT07284654 · 4,049 participants · Start Dec 1, 2025 · Primary completion Sep 17, 2026
Drug: 31 valent pneumococcal conjugate vaccine; PCV20 and 1 more · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Chinle, Arizona; Whiteriver, Arizona · 30 sites in all
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06824194 · 2,360 participants · Start Feb 18, 2025 · Primary completion Oct 22, 2027
Drug: PCV21 vaccine; Prevnar 20 vaccine and 8 more · For: Pneumococcal Immunization
Sites: Birmingham, Alabama; Guntersville, Alabama; Oneonta, Alabama · 132 sites in all
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07348692 · 2,195 participants (planned) · Start Jan 20, 2026 · Primary completion Jun 7, 2027
Drug: PCV21 vaccine; 20vPCV licensed vaccine · For: Pneumococcal Immunization; Healthy Volunteers
Sites: Fayetteville, Arkansas; Huntington Park, California; Los Angeles, California · 25 sites in all
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePivotal-lookingActive, not recruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06736041 · 1,714 participants · Start Dec 18, 2024 · Primary completion May 17, 2027
Drug: PCV21 vaccine; Prevnar 20 vaccine and 5 more · For: Pneumococcal Immunization
Sites: Glendale, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 112 sites in all
- Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsPivotal-lookingActive, not recruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06838000 · 1,268 participants · Start Feb 28, 2025 · Primary completion Dec 1, 2026
Drug: PCV21; 20vPCV · For: Pneumococcal Infections
Sites: Paramount, California; Doral, Florida; Hialeah, Florida · 38 sites in all
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06975878 · 1,092 participants · Start May 22, 2025 · Primary completion Aug 25, 2027
Drug: PCV21 vaccine; Vaxneuvance vaccine and 3 more · For: Pneumococcal Immunization; Healthy Volunteers
Sites: Alken, Belgium; Bruges, Belgium; Edegem, Belgium · 49 sites in all
- Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in AdultsPivotal-lookingRecruiting
Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
NCT06822907 · 1,052 participants (planned) · Start Dec 17, 2025 · Primary completion Oct 1, 2028
Drug: Early intervention; Delayed intervention · For: Acute Febrile Illness; Pneumococcal Infections
Sites: Saint-Etienne, France; Annecy, France; Besançon, France · 24 sites in all
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06824181 · 580 participants · Start Feb 27, 2025 · Primary completion Sep 10, 2027
Drug: PCV21 vaccine; Prevnar 20 vaccine and 8 more · For: Pneumococcal Immunization
Sites: Los Angeles, California; Hollywood, Florida; Miami, Florida · 27 sites in all
- Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug UsePivotal-lookingRecruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT06829238 · 100 participants (planned) · Start Apr 7, 2025 · Primary completion Nov 30, 2028
Drug: Metformin; Placebo and 2 more · For: Systemic Inflammation; Immune Dysregulation; Injection Drug Use and 1 more
Sites: Birmingham, Alabama
- Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07247188 · 100 participants (planned) · Start Jan 20, 2026 · Primary completion Jan 7, 2027
Drug: PCV21; 20vPCV · For: Sickle Cell Disease
Sites: Atlanta, Georgia; Omaha, Nebraska; New Brunswick, New Jersey · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adultsߙࣙ65ߙyears of age in Denmark.
Sharomi O, Oidtman RJ, Lang JC, et al. · Expert Rev Pharmacoecon Outcomes Res 2026
- Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024.
Rieger R, Yahav D, Margalit I, et al. · Euro Surveill 2026
- Pneumococcal Vaccination of Adults in Italy: What Strategies?
Massaro E, Gabutti G · J Prev Med Hyg 2025
- Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Wateska AR, Nowalk MP, Lin CJ, et al. · Vaccine 2023
Also in development for Pneumococcal Immunization
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- M-M-R II vaccinePhase 33 trials
Sanofi · Pneumococcal Immunization
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.